Pentosan Polysulfate Treatment of Mucopolysaccharidosis Type IIIA Mice

Area of Science:

• Biomedical Research
• Neuroscience
• Genetics

Background:

• Mucopolysaccharidosis (MPS) type IIIA, or Sanfilippo A syndrome, is a rare genetic disorder.
• It leads to progressive neurodegeneration and severe cognitive impairment due to lysosomal enzyme deficiency.
• Current treatments are limited, necessitating research into novel therapeutic strategies.

Purpose of the Study:

• To evaluate the therapeutic impact of pentosan polysulfate (PPS) on MPS type IIIA mice.
• To compare the efficacy of subcutaneous (subQ) versus intracerebroventricular (ICV) PPS administration.
• To assess PPS effects on neuroinflammation, neurodegeneration, and behavior in MPS IIIA.

Main Methods:

• Three groups of MPS IIIA mice received different PPS treatments (early subQ, later subQ, continuous ICV infusion).
• Evaluations included plasma cytokine analysis, systemic organ histology, and brain markers for neuroinflammation, neurodegeneration, and lysosomal disease.
• Neurobehavioral tests were conducted to assess functional outcomes.

Main Results:

• Subcutaneous PPS reduced systemic inflammation (cytokines, macrophage infiltration).
• SubQ PPS significantly improved brain neuropathology, neuroinflammation, and behavioral deficits in MPS IIIA mice.
• Early subQ treatment demonstrated more pronounced effects than dose, and ICV administration showed intermediate effects.

Conclusions:

• Subcutaneous administration of pentosan polysulfate is a promising therapeutic approach for MPS type IIIA.
• Early intervention with subQ PPS offers significant benefits for neurological and behavioral symptoms.
• Further research is warranted to optimize PPS delivery and dosing for Sanfilippo A syndrome.